In the past 4 years, many publications described a concentration-dependent deposition of
gadolinium in the brain both in adults and children, seen as high signal intensities in the …

Gadolinium-based contrast agents (GBCAs) are commonly used for enhancement in MR
imaging and have long been considered safe when administered at recommended doses …

For magnetic resonance, the established class of intravenous contrast media is the
gadolinium-based contrast agents. In the 3 decades since initial approval, these have …

In 2014, for the first time, visible hyperintensities on unenhanced T1-weighted images in the
nucleus dentatus and globus pallidus of the brain were associated with previous Gadolinium …

Pharmaceutical drugs have become consumer products, with a daily use for some of them.
The volume of production and consumption of drugs is such that they have become …

Since its introduction more than 35 years ago, gadolinium-enhanced MRI has fundamentally
changed medical practice. Although extraordinarily safe, gadolinium-based contrast agents …

Objectives”, explains how to select and use various test methods for evaluating disease
states, the prognosis, and the effects of treatment. References to the literature published …

Until 2006, the main considerations regarding safety for all gadolinium-based contrast
agents (GBCAs) were related to short-term adverse reactions. However, the administration …

Abstract The Pharmacovigilance Risk Assessment Committee (PRAC) of the European
Medicines Agency (EMA) earlier this year recommended to suspend some marketing …

Gadolinium-based contrast agents (GBCA), widely used in Magnetic Resonance Imaging
(MRI) for almost 30 years, were recently shown to be deposited in the brain and to induce …